solute carrier family 16 member 4Genealiases: MCT4 · MCT5
Q-omics provides the consensus-scored SLC16A4 profile across patient tissues and cancer cell-line models. SLC16A4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC16A4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SLC16A4 RNA expression shows 20,184 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where SLC16A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC16A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC16A4 survival associations across molecular data types. SLC16A4 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC16A4 RNA expression–survival associations across cancer types. High SLC16A4 expression shows unfavorable associations in LGG, LUAD, BLCA and UCEC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC16A4 RNA expression.
This table summarizes SLC16A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC16A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC16A4 shows lower tumor expression in KICH, UCEC, LUSC, LIHC and BLCA and higher tumor expression in COAD. The KICH box plot shows higher SLC16A4 RNA expression in normal versus tumor tissue (log2 FC = −5.960, t-test p < 0.001).
This table shows molecular features associated with SLC16A4 in patient tissues and cancer cell lines. In patient samples, SLC16A4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC16A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
